Professor Robert A. Harris
Professor Robert A. Harris (Bob) was born in Harpenden in Southern UK in 1966. He conducted a Bsc.Hons undergraduate degree at Portsmouth Polytechnic, majoring in Parasitology in 1987. PhD studies at University College London studying innate immune agglutinins in Schistosoma host snail species with Terry Preston and Vaughan Southgate as supervisors culminated with a thesis defence in early 1991. A 2.5 year postdoc at the London School of Hygiene & Tropical Medicine in Paul Kaye’s research group ensued, with focus on understanding the intracellular fate of Leishmania spp. protozoans in macrophages. Bob was awarded a Wellcome Trust postdoctoral fellowship that permitted his relocation to the Karolinska Institutet (Stockholm, Sweden) in the spring of 1994. A postdoc period was spent split between the labs of Anders Örn and Tomas Olsson, in which he studied Trypanosoma cruzi and Trypanosoma bruceii protozoan proteins. Bob became an Associate Professor at the Karolinska Institutet in 1999, heralding his establishment as a PI. Bob started to work with autoimmune diseases in 1996 and began study of therapy using live parasite infections or parasite molecules. His research group has developed autoantigen-specific vaccines, defined the effects of post-translational biochemical molecules on autoantigenicity and developed a macrophage adoptive transfer therapy that prevents pathogenesis in several experimental disease models. He became Professor of Immunotherapy in Neurological Diseases in 2013. In recent years research focus has centred on understanding the immunopathogenesis of incurable neurodegenerative diseases, with particular emphasis on development of immunotherapies directed at microglial cells as potential therapeutic paradigms.
Bob Harris CV July 2020
ERIK HERLENIUS GROUP
Development of autonomic control
Immature or deficient autonomic control is a common problem in infants born at a premature age and is of central importance in apneas, secondary hypoxic brain damage and sudden infant death syndrome.
PER ERIKSSON GROUP
For better understanding of disturbances in respiratory control we study early development of cardiorespiratory control, brainstem neural networks and its associations with normal and pathological breathing. The conceptual change introduced by our recent data that endogenous prostaglandins are central pathogenic factors in respiratory disorders and the hypoxic response, open new diagnostic and therapeutic avenues that should significantly better the diagnostics and treatment of newborns and adult patients.
Inflammation is a major culprit in breathing disorders and we hypothesize that by using a newly developed urinary prostaglandin biomarker we can screen, detect and protect against inflammation related breathing disorders.
Our collaborative efforts enable us to move from a clinical problem to molecular understanding of the disease and studies are performed in patients, animal & in vitro models.
Our research is focused on the development of autonomic control with normal and paediatric patients as the target. Autonomic dysfunction in breathing and circulatory control often has its origin in neurodevelopment disorders. Furthermore, our basic research in developmental neuroscience how neural activity and stem cells form activity dependent networks is vital for the development of therapeutic interventions.
CENTER FOR MOLECULAR MEDICINE
PER SVENNINGSSON GROUP
Parkinson´s disease and depression are common disorders with largely unknown etiologies. There is a need for disease-modifying therapies in these disease states. The Section of Translational Neuropharmacology studies these disease states at a molecular and cellular level both in preclinical models and in specimens from patients. The goal is to identify novel targets for improved diagnostics and pharmacological receptor-based treatments. It is important for receptors to be properly located in nerve cell to properly activate relevant intracellular signaling cascades. The laboratory studies the dynamics of the localization and functionality of receptors. A working hypothesis is that altered levels of receptors in a certain compartment of a nerve cell can underlie pathology. In that respect experiments are focused on identifying and study adaptor proteins and lipids which bind to receptors and regulate their localization and function. Biochemical, histological, pharmacological, molecular biological and behavioral techniques are being used in the laboratory.
Ellen Hertz (2020)
Henrik Sjöström (2020)
Mark Zurbrügg (2019)
Cyril Monnot (2018)
Martin Paucar (2017)
Alvarsson, Alexandra (2015)
Shrestha, Stal Saurav (2014)
Tiberiu Stan (2014)
Ebba Gregersson Lundius (2013)
Mikael Skorpil (2012)
Martin Egeland (2012)
Kiselycznyk, Carly (2012)
Eriksson, Therese M. (2012)
Pålhagen, Sven E (2009)
Hongshi Qi (2009)
Xiaquin Zhang (2008)
Sjögren, Benita (2008)
Eriksson T, Delagrange P, Spedding M, Popoli M, Mathé A, Ögren S, et al. Emotional memory impairments in a genetic rat model of depression: involvement of 5-HT/MEK/Arc signaling in restoration. Mol. Psychiatry 2012 Feb;17(2):173-84.
Madeira A, Ohman E, Nilsson A, Sjögren B, Andrén P, Svenningsson P. Coupling surface plasmon resonance to mass spectrometry to discover novel protein-protein interactions. Nat Protoc 2009 ;4(7):1023-37.
Zhang X, Andren P, Greengard P, Svenningsson P. Evidence for a role of the 5-HT1B receptor and its adaptor protein, p11, in L-DOPA treatment of an animal model of Parkinsonism. Proc. Natl. Acad. Sci. U.S.A. 2008 Feb;105(6):2163-8.
Svenningsson P, Chergui K, Rachleff I, Flajolet M, Zhang X, El Yacoubi M, et al. Alterations in 5-HT1B receptor function by p11 in depression-like states. Science 2006 Jan;311(5757):77-80.
Svenningsson P, Tzavara E, Carruthers R, Rachleff I, Wattler S, Nehls M, et al. Diverse psychotomimetics act through a common signaling pathway. Science 2003 Nov;302(5649):1412-5.